Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas (Q33655854)

28 July 2017

1 reference

title

Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas (English)

1 reference

magnetic resonance imaging

28 July 2017

main subject

0 references

2

Peter Hau

0 references

author name string

Frederic G Dhermain

1

1 reference

28 July 2017

Peter Hau

2

1 reference

28 July 2017

Heinrich Lanfermann

3

1 reference

28 July 2017

Andreas H Jacobs

4

1 reference

28 July 2017

Martin J van den Bent

5

1 reference

28 July 2017

publication date

10 August 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

9

1 reference

28 July 2017

issue

9

1 reference

28 July 2017

page(s)

906-920

1 reference

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Nuclear imaging probes: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Prognostic value of choline and creatine in WHO grade II gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

(1)H MRSI and progression-free survival in patients with WHO grades II and III gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Oncogenic alterations of metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

On the Origin of Cancer Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Physiologic and metabolic magnetic resonance imaging in gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Imaging in neurooncology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

A comparison of Ktrans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Effect of intravascular-to-extravascular water exchange on the determination of blood-to-tissue transfer constant by magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Estimate of vascular permeability and cerebral blood volume using Gd-DTPA contrast enhancement and dynamic T2*-weighted MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Dexamethasone normalizes brain tumor hemodynamics as indicated by dynamic susceptibility contrast MRI perfusion parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

The parametric response map is an imaging biomarker for early cancer treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

High-grade glioma before and after treatment with radiation and Avastin: initial observations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced pe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Perfusion MR imaging: moving forward.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Diffusion imaging: insight to cell status and cytoarchitecture

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

MRI quantification of non-Gaussian water diffusion by kurtosis analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Glioma surgery using a multimodal navigation system with integrated metabolic images

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Early metabolic responses in temozolomide treated low-grade glioma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

Clinical and radiographic features of peritumoral infarction following resection of glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970181-2

7 January 2021

10.1016/S1474-4422(10)70181-2

Identifiers

DOI

1 reference

28 July 2017

1 reference